Therapeutic cancer vaccines aim to stimulate tumor-specific immune responses and are being explored in PDAC as whole-cell (e.g., GVAX) [80], peptide-based (e.g., GV1001, MUC-1) [81,82], and dendritic cell-based vaccines [83]. This evidence concerns the gene MUC1 and cancer.